A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants
Status:
Completed
Trial end date:
2021-03-08
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to conduct blood tests to measure how much pirtobrutinib
(LOXO-305) is in the bloodstream and how the body handles and eliminates pirtobrutinib
(LOXO-305) after meals and on an empty stomach. The study will also evaluate the safety and
tolerability of pirtobrutinib (LOXO-305). Participants will stay in this study for up to 53
days (screening through follow-up call).